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Abstract
Fanconi anemia (FA) is a rare inherited disorder clinically characterized by congenital malformations, progressive bonemarrow
failure and cancer susceptibility. At the cellular level, FA is associated with hypersensitivity to DNA-crosslinking genotoxins.
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Eight of 17 known FA genes assemble the FA E3 ligase complex, which catalyzesmonoubiquitination of FANCD2 and is essential
for replicative DNA crosslink repair. Here, we identify the ﬁrst FA patient with biallelic germline mutations in the ubiquitin E2
conjugase UBE2T. Both mutations were aluY-mediated: a paternal deletion and maternal duplication of exons 2–6. These
loss-of-functionmutations in UBE2T induced a cellular phenotype similar to biallelic defects in early FA geneswith the absence
of FANCD2monoubiquitination. Thematernal duplication produced amutantmRNA that could encode a functional protein but
was degraded by nonsense-mediated mRNA decay. In the patient’s hematopoietic stem cells, the maternal allele with the
duplication of exons 2–6 spontaneously reverted to a wild-type allele by monoallelic recombination at the duplicated aluY
repeat, thereby preventing bone marrow failure. Analysis of germline DNA of 814 normal individuals and 850 breast cancer
patients for deletion or duplication of UBE2T exons 2–6 identiﬁed the deletion in only two controls, suggesting aluY-mediated
recombinations within the UBE2T locus are rare and not associated with an increased breast cancer risk. Finally, a loss-of-
function germline mutation in UBE2Twas detected in a high-risk breast cancer patient with wild-type BRCA1/2. Cumulatively,
we identiﬁed UBE2T as a bona ﬁde FA gene (FANCT) that also may be a rare cancer susceptibility gene.
Introduction
Fanconi anemia (FA) is an autosomal or X-linked recessive inher-
ited DNA instability disorder that is caused by germline muta-
tions in at least 17 genes (FANCA, FANCB, FANCC, FANCD1/
BRCA2, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ/BRIP1,
FANCL, FANCM, FANCN/PALB2, FANCO/RAD51C, FANCP/SLX4,
FANCQ/ERCC4 and FANCS/BRCA1) that are involved in the DNA
damage response (1–4). Clinically, FA is characterized by variable
congenital abnormalities, progressive bone marrow failure,
endocrine abnormalities and a predisposition to malignancies,
primarily acute myelogenous leukemia and solid tumors (5–8).
In the absence of congenital abnormalities, FA is usually diag-
nosed based on the onset of bone marrow failure ranging from
mild to severe within the ﬁrst decade of life (5,9,10). An analysis
of 754 North American FA patients enrolled in the International
Fanconi Anemia Registry (IFAR) demonstrated that the average
age of hematological onset of FA is 7.6 years (5). However, as
FANCA, FANCC and FANCG are the most frequently mutated FA
genes (5,9,11), the onset of bone marrow failure might differ in
FA patients with rarer gene defects (2,4,12–15). If bone marrow
failure does not occur due to the presence of a ‘milder’ mutation
with residual protein function or due to mosaicism in the hem-
atopoietic system as a consequence of a gain-of-function muta-
tion in hematopoietic stem cells (16–19), the diagnosis of FA is
oftenmade upon presentationwith cancer orwith severe toxicity
after treatment of a malignancy with chemotherapy (5,20,21).
Cells from FA patients exhibit a distinctive cellular phenotype
of hypersensitivity to DNA interstrand crosslinking agents such
as mitomycin C (MMC) and diepoxybutane (DEB), which can be
assessed as increased chromosomal breakage in metaphase
and by G2 cell cycle arrest using ﬂow cytometry (22–24). Upon
recognition of a stalled replication fork in S phase at a DNA inter-
strand crosslink (ICL), a core protein complex formed by the pro-
ducts of eight FA genes (A/B/C/E/F/G/L/M) is activated via
ATR-mediated phosphorylation and recruited to the sites of ICL
lesions. Subsequently, FANCL, the FA core complex subunit
with E3 RING ligase activity, monoubiquitylates the FANCI/
FANCD2 (I/D2) protein dimer formed by the products of the two
FA genes FANCD2 and FANCI at corresponding lysine residues
in each protein (3,25,26). This activation process is critically de-
pendent on the presence of all eight FA core complex gene pro-
ducts and additional accessory FA-associated proteins such as
FAAP20, −24 and−100. The E2 conjugase UBE2T, which is thought
to be recruited independently of the FA core complex to damaged
chromatin, speciﬁcally binds to FANCL to promote the site-
speciﬁc monoubiquitination of FANCD2 and FANCI (27–32). The
products of the other FA genes D1/BRCA2, J/BRIP1, N/PALB2,
O/RAD51C, P/SLX4, Q/ERCC4, and S/BRCA1 are dispensable for
the monoubiquitination of FANCD2 and FANCI and therefore
are classiﬁed as downstream components of the FA pathway
(3,4,25,26). These FA proteins are involved in later stages of the
ICL repair and are essential players in homologous recombin-
ation (HR) repair. Importantly, heterozygous germline mutations
in these late/downstreamgenes predispose individuals to several
malignancies, such as breast, ovarian and pancreatic cancers
(33–35).
Results
Clinical presentation
The most distinct and indicative cellular defects in FA patient-
derived cells are hypersensitivity to lowdoses of DNA crosslinking
agents, such MMC or DEB, and high frequencies of chromosomal
abnormalities (36). Even today, a small percentage of individuals
are diagnosed by pathological chromosomal breakage tests, but
exhibit no pathogenic mutations in known FA/DNA repair genes.
One such individual is the 16-year-old FA patient 100166/1 who
has American parents with solely Italian ancestry. Except for the
thalassemia trait, this patient has no family history of genetic pre-
disposition for cancer or an increased miscarriage frequency. The
patientwas bornwith bilateralmalformations of both thumbs and
radii and small stature. Within the ﬁrst week of life, he was diag-
nosed as being affected by FA due to high levels of DEB-induced
high chromosomal breakage in metaphases of hematopoietic
cells: baseline 0.1 and 5.8 breaks/cell in the absence or presence
of 0.1 µg/ml DEB (normal 0.0–0.05 and 0.00–0.1, respectively).
However, a facial appearance atypical for FA, normal bonemarrow
cellularity, normal leukocyte and thrombocyte counts after the
perinatal period, mild anemia with a low mean corpuscular vol-
ume (Supplementary Material, Fig. S1) due to a thalassaemia
minor mutation inherited from his father, and the failure to iden-
tify germline mutations in DNA repair genes prevented a clear
genetic diagnosis for the ﬁrst 16 years of his life.
A defect in FANCD2 monoubiquitination in the patient’s
ﬁbroblasts
For initial diagnostic classiﬁcation, we performed a standard
chromosomal breakage analysis using DEB as a genotoxin in the
primary FA 100166/1 skin ﬁbroblasts obtained from the patient at
2 years of age. The results shown in Table 1 clearly demonstrate
that the ﬁbroblast cells possessed the typical characteristic
hypersensitivity of FA cells towards DEB, compared with normal
ﬁbroblasts and the highly sensitive fetal FANCG−/− reference
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ﬁbroblasts. Asanestablisheddiagnostic tool in the classiﬁcationof
FA patients (37), we next performed western blotting analysis on
immortalized FA100166/1 ﬁbroblasts, which revealed that expos-
ure of the cells to MMC overnight did not lead tomonoubiquitina-
tion of FANCD2 (Fig. 1A, lane 3), a central activation step in the FA
pathway that is dependent on thenormal functionof the ‘early’ FA
genes and also includes FANCI (1). Therefore, we transduced pri-
maryskinﬁbroblasts of thepatientwith a series ofG418-selectable
retroviral vectors that expressed the cDNAs of FANCA/B/C/E/F/G/L/
I similarly, as describedpreviously (13). Stably transducedG418-re-
sistant primary ﬁbroblasts were incubatedwith low doses of MMC
(0, 45 or 60 n). Cell cycle analysis after 3 days revealed that the pa-
tient’s ﬁbroblasts were clearly hypersensitive to the ICL lesions.
However, none of the retroviral vectors corrected the MMC-
induced G2 arrest of the ﬁbroblasts (Supplementary Material,
Fig. S2). We therefore hypothesized that this patient had a defect
in a yet unidentiﬁed FA gene.
Retroviral complementation identiﬁes UBE2T
as a new FA gene
Candidate genes (FAAP20, FAAP24, FAAP100 and UBE2T), for
which deﬁciencies have been associated with defective FANCD2
monoubiquitination (27,39–43), were introduced into FA 100166/1
primary skin ﬁbroblasts using G418-selectable retroviral expres-
sion vectors (13). Of all analyzed cDNAs, only expression of
UBE2T (RefSeq: NM_014176.3) completely abrogated the cellular
hypersensitivity towards 45 and 60 nMMC (Fig. 1B and Supple-
mentary Material, Fig. S3). Western blot analysis of whole cell
lysates revealed that FANCD2 monoubiquitination was restored
in UBE2T-transduced cells comparable to the FANCD2-L levels
(D2-L) obtained in wild-type (WT) ﬁbroblasts and in FANCL-
deﬁcient ﬁbroblasts complemented by a speciﬁc FANCL virus
(Fig. 1A lanes 2, 5 and 7). Using a polyclonal UBE2T antibody
(44), we demonstrated that the endogenous UBE2T protein was
largely absent in non-transduced and control vector-transduced
patient ﬁbroblasts, but abundantly detected in cells transduced
with the UBE2T-expressing vector (Fig. 1C lanes 3 and 4). We
and others previously showed that FANCL also binds to another
E2 conjugase, UBE2W (29,45). However, expression of UBE2W
in ﬁbroblasts from patient 100166/1 did not rescue the MMC-
induced cell cycle arrest (Supplementary Material, Fig. S4).
These results strongly suggest that the patient inherited two
germline mutations in UBE2T and that this E2 conjugase is the
18th FA gene, FANCT.
Identiﬁcation of two germline mutations, a deletion
and a duplication, in UBE2T due to aluY-mediated
recombination
To conﬁrm the results of the functional complementation and
biochemical experiments, each exon of theUBE2T gene including
the splice junctions was sequenced using the genomic DNA
of patient 100166/1 ﬁbroblasts. We could not identify any patho-
genic mutation in the genomic DNA at the UBE2T locus either by
capillary Sanger or whole exome sequencing (data not shown).
We also did not detect any pathogenic mutations in the genomic
5′ promoter and the 3′ untranslated regions (UTRs) of the UBE2T
gene (data not shown). Sanger sequencing conﬁrmed the pres-
ence of two 311-bp aluY elements in identical orientation in
intron 1 and intron 6 with 5′ long stretches of T nucleotides (Sup-
plementary Material, Fig. S5). In our patient, both aluY elements
were 100% identical, in contrast to the current assembly of the
human genome, GRCh38.p2, where the two aluY elements con-
tain a single mismatch at position 192. Surprisingly, sequencing
of a large proportion of the introns in genomic DNA from the FA
100166/1 ﬁbroblasts revealed the presence of only three heterozy-
gous single nucleotide polymorphisms (SNPs), one of which was
located in intron 6 (Supplementary Material, Fig. S6), thus sug-
gesting a large genomic deletion in at least one allele. However,
semi-quantitative PCR for all seven exons of UBE2T suggested
that all exons were present in the ﬁbroblasts at normal dosages
(data not shown). In addition, linkage analysis performed on
the family using SNPs on theAffymetrix 6.0 array did not indicate
that the parents were consanguineous for the UBE2T locus on
chromosome 1 (data not shown).
To test for a deletion,we used exon 1F and 7R primers in cDNA
and ampliﬁed a normal allele from the sample obtained from the
patient at 14 years of age, aswell as samples from themother and
father (Fig. 2A, lanes 1, 3 and 4). We detected a shorter mutant
allele in the cDNA from the patient’s peripheral blood and ﬁbro-
blasts and in that from the father (Fig. 2A, lanes 1, 2 and 4). Se-
quencing of the PCR products conﬁrmed the presence of the
normal allele and revealed that themutantUBE2Tallele inherited
from the father was missing exons 2–6 (Fig. 2A).
We hypothesized that a more complex genomic rearrange-
mentmight have occurred on thematernal allele. To test for a du-
plication within the UBE2T locus, we generated cDNA using the
primary ﬁbroblasts from the patient and peripheral blood from
a normal individual and from the mother and father. Surprising-
ly, we were able to speciﬁcally amplify a 585-bp product with a
pair of non-overlapping exon 2F and exon 2R primers (Fig. 2B
2F_2R, lanes 2 and 3) that generated a 54-bp product of exon 2
in the normal UBE2T gene locus (2F_2R, lanes 1–4), thus clearly
demonstrating that additional genomic material was present at
the mRNA level in the patient’s ﬁbroblasts and the mother’s leu-
kocytes. Using combinations of exon 6F and exons 2, 3, 4, 5, 6 and
7 reverse primers shown in Figure 2B followed by sequencing of
the ampliﬁed products revealed the presence of a duplication of
exons 2–6 at the mRNA level in the patient’s ﬁbroblasts and the
mother’s peripheral blood (Fig. 2B, lanes 2 and 3).
In summary, we hypothesized that the patient inherited a
large intragenic deletion in UBE2T from his father, creating a
new intron between exons 1 and 7 that contained only one
aluY element and the adjacent nucleotides of the 5′ part of intron
1 and the 3′ part of intron 6, respectively (Fig. 2C). As the transla-
tional start of UBE2T is in exon 2, no mutant UBE2T protein is ex-
pressed from the paternal allele. From his mother, the patient
inherited a duplication of exons 2–6 including all intronic se-
quences and one additional alu element, thus generating a
Table 1. Metaphase chromosomal breakage analysis of primary
ﬁbroblasts
Sample DEB dose
(µg/ml)
Number of
metaphases
scored
Total
number of
breaks
Breaks
per Cell
Fetal ﬁbroblast
94–38
0 66 4 0.06
(FANCG−/−) 0.01 49 47 0.96
0.1 1 5 5.00
FA 100166/1 0 52 15 0.29
(UBE2T−/−) 0.01 50 44 0.88
0.05 50 101 2.02
0.1 50 140 2.80
NL1433889 0 50 0 0.00
(normal control) 0.01 47 2 0.04
0.1 47 7 0.15
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UBE2T allele with three identical aluY elements in identical
orientation (Fig. 2C).
Reversion of the mutant allele inherited from the mother
by monoallelic aluY-mediated recombination
To conﬁrm these rearrangements in genomic DNA and to under-
stand the appearance of a normal allele in the peripheral blood
cells of the patient (Fig. 2A, lane 1), we developed two distinct
PCRs as outlined in Figure 2C for co-amplifying the normal as
well as amutant allele in one reaction. The PCR analyses on gen-
omic DNA showed that the patient inherited the aluY-mediated
duplication of UBE2T from his mother (Fig. 2C, lanes 1, 4 and 7).
However, the duplication was not present in the genomic DNA
from the patient’s peripheral blood nor in a EBV-transformed B-
cell line newly established when the patient was 14 years of age
(lanes 2 and 5). It also was not detected in the father (lanes 3 and
6). Combined, these results demonstrate that the duplication of
exons 2–6 in UBE2T was lost in the hematopoietic system of the
patient, thus proving that the normal thrombocytes and platelet
counts observed after the perinatal period were due to somatic
mosaicism. The strong in vivo selective advantage of phenotypic-
ally normal stem cells and their progeny led to replacement of
the defective FA hematopoiesis over time, thus preventing the
development of bone marrow failure. The second mutation in-
herited from the father was not subject to reversion and thus
was detected in all genomic DNA from the patient and his father
(Fig. 2C, lanes 8–10, 12–13), but not in the DNA from his mother
(lanes 11 and 14). Sequencing of the PCR products conﬁrmed
that the rearrangements of the duplication and the deletion as
well as the reversion had occurred at the aluY repeats within
the UBE2T locus.
The maternal allele encodes an mRNA for a shorter
functional UBE2T protein that is degraded
by nonsense-mediated mRNA decay
Theoretically, the duplication of exons 2–6 within the maternal
allele should lead to an mRNA with a shortened open reading
frame encoding 162 amino acids with a frameshift at position
c.469 due to the addition of the ﬁrst 10 base pairs of exon 2–6
(Fig. 2C and Supplementary Material, Fig. S7). This mutant pro-
tein (UBE2T 468fs) contained the complete UBC domain (5–152)
followed by six mutant amino acids (157–162), but lacked the ter-
minal 41 amino acids of the WT protein. The ﬁrst open reading
frame of this mutant was followed by the correct arrangement
of exons 2–7, which could encode the entire wild-type protein.
We therefore cloned the ﬁrst shorter mutant ORF (UBE2T 468fs)
into a retroviral vector and stably expressed the mutant protein
in Ube2t−/− DT40 cells. Western blotting on transduced DT40
cells demonstrated that the shorter protein was expressed
at high levels (Fig. 3A). Importantly, this mutant protein was
capable of ensuring the survival of Ube2t−/− DT40 cells when
challenged with MMC, similar to WT UBE2T protein (Fig. 3B).
However, as the shorter protein of 162 amino acids from the
maternal allele was never detected in the patient’s ﬁbroblasts
Figure 1. Identiﬁcation ofUBE2T as new FA gene by retroviral complementation of
FA 100166/1 ﬁbroblasts and western blotting. (A) Western blot analysis of protein
extracts from transduced ﬁbroblast lines immunostained with a FANCD2
antibody to detect non-ubiquitinated (D2-S) and monoubiquitinated (D2-L)
FANCD2. Lanes 1–3 depict the FANCD2 ubiquitination status of FANCC-deﬁcient
(FA-C), wild-type (WT) and FA100166/1 ﬁbroblasts exposed to 150 n MMC
overnight. Lanes 4–7 show the FANCD2 monoubiquitination status of G418-
resistant FA 100166/1 and FANCL-deﬁcient ﬁbroblasts, genetically modiﬁed with
a control vector or with vectors expressing UBE2T or FANCL cDNAs, respectively.
Staining with a RAD50 antibody was used to visually conﬁrm equal loading. (B)
Flow cytometric cell cycle analysis of transduced primary ﬁbroblasts grown for
3 days in 0, 45 or 60 n MMC. FA-G: primary FANCG−/− ﬁbroblasts (38)
transduced with the control vector (neo control). FA 100166/1: primary patient
ﬁbroblasts transduced with the control vector (neo control) or the UBE2T-
coexpressing vector (UBE2T + neo). The distribution of cells in G0/G1, S and G2/M
arrest from three different experiments is shown. (C) Western blot analysis of
protein extracts from the indicated cells upon staining with a polyclonal
antibody speciﬁc for human UBE2T protein. HEK293T cells, immortalized
ﬁbroblasts from a healthy donor (normal) and from a FANCQ/ERCC4/XPF
deﬁcient (XPF−/−) patient were used as positive controls. Analysis of non-
transduced or transduced immortalized FA patient cells (FA 100166/1) showed
speciﬁc restoration of the absent UBE2T protein by the UBE2T retrovirus.
Staining with a GAPDH antibody was used to visually conﬁrm equal loading.
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Figure 2. Identiﬁcation of two aluY-mediated germlinemutations inUBE2T in FA 100166/1. (A) Identiﬁcation of the paternal exons 2–6 deletion inUBE2T in cDNA. Forward
and reverse primers in exons 1 (1F) and 7 (7R) were utilized in cDNA from the peripheral blood (PB) and ﬁbroblasts (ﬁbro) of the FA 100166/1 patient. The PB from the patient
was sampled at 14 years of age. cDNAwas also obtained from the PB of themother (PBMother) and father (PB Father). The ampliﬁed PCRproductswere run ona gel, and the
bands excised and sequenced. Sequencing traces for two of the band are shown. Boundaries of the different exons are indicated. (B) Identiﬁcation of the maternal exons
2–6 duplication inUBE2T in cDNA. cDNAwas generated fromthe primary ﬁbroblasts of the patient (Fibro patient) and the PB of a normal individual (PB control), themother
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by western blotting, we hypothesized that the mRNA generated
from the maternal allele may not be stable due to the entire
mRNA structure with the premature stop in the duplicated se-
cond exon 2. In general, mutations that generate premature
stops can result in low levels of mutant mRNA owing to degrad-
ation by nonsense-mediated mRNA decay (NMD) (46–48), which
is one of the main RNA surveillance mechanisms in cells. To
test the hypothesis that the mutated UBE2T mRNA from the du-
plicationwas being destroyed byNMD, thereby explaining the ab-
sence of the expected UBE2T 468fs protein in the FA 100166/1
ﬁbroblasts, we treated the ﬁbroblasts with different doses of cy-
cloheximide, a known inhibitor of NMD (49), and analyzed the
mRNA by RT-PCR. PCR ampliﬁcation revealed a clear increase of
the mutant maternal allele in the ﬁbroblast cDNA following cy-
cloheximide treatment (Fig. 3C), demonstrating that the mRNA
from the maternal duplication was indeed degraded by NMD.
Characterization of an early FA phenotype in patient
UBE2T−/− ﬁbroblasts
We next analyzed the patient’s ﬁbroblasts for defects related to
the function(s) of FA proteins. For this purpose, we used immor-
talized UBE2T−/− ﬁbroblasts (FA 100166/1T) to generate isogenic
pairs by transduction either with a UBE2T-expressing vector
or the corresponding control vector and characterized their sen-
sitivities toward known genotoxic agents (Fig. 4A). Non-corrected
UBE2T−/− cells (control) were hypersensitive to cisplatin, but
this was attenuated by UBE2T expression. In contrast, UBE2T-
dependent hypersensitivity towards ionizing radiation or the
topoisomerase I inhibitor camptothecin was not detected. This
sensitivity proﬁle ﬁts well with previously published results in
Ube2t−/− DT40 cells (44) and with other patient-derived FA cells
with deﬁcient monoubiquitination of FANCD2 (3,25,26).
We next assessed FANCD2 and FANCI monoubiquitination in
response to MMC and also FANCD2 recruitment to sites of DNA
lesions in the UBE2T−/− ﬁbroblasts. MMC-induced FANCD2 and
also FANCI monoubiquitination was not detectable in immorta-
lized UBE2T−/− FA 100166/1 ﬁbroblasts (Fig. 4B). In addition,
FANCD2 recruitment to sites of interstrand crosslinks (ICLs), vi-
sualized by γ-H2AX staining of UVA laser track-induced psoralen
crosslinks, did not occur in UBE2T−/− cells (Fig. 4C). Importantly,
UBE2T−/− cells transduced with the UBE2T expression vector re-
gained FANCD2 and FANCImonoubiquitination and also FANCD2
accumulation at the sites of psoralen laser tracks (Fig. 4B and C),
thus conﬁrming the essential role of the human E2 conjugating
enzyme UBE2T for FANCD2 and FANCI monoubiquitination and
ICL repair.
Frequencies of aluY-mediated rearrangements in the
UBE2T locus
As both parents were of Italian origin with ancestors coming
from Sicily, we next analyzed the frequencies of the duplication
and deletion of UBE2T exons 2–6 in germline DNA from normal
individuals from Northern Italy and Sicily. A total of 706 alleles
from Sicily and 662 alleles from Northern Italy were tested. In
addition, we analyzed the genomic DNA of 532 alleles from
blood donors of German descent. Using the PCR approach de-
scribed above, we detected the aluY-mediated deletion of
UBE2T exons 2–6 in only two healthy individuals, one from Nor-
thern Italy and one from Germany (Fig. 5A and B). We did not de-
tect the duplication in any of the 1900 alleles from the healthy
controls. Unfortunately, genomic DNA from the maternal pedi-
gree was not available for further analysis.
Germline mutations in UBE2T in breast cancer patients
At least 5 of the 17 known FA genes, D1/BRCA2, J/BRIP1, N/PALB2,
O/RAD51C and S/BRCA1, are well-established breast and/or ovar-
ian cancer susceptibility genes (33,50,51). Although heterozygote
germlinemutation carriers with defects in these late FA genes are
at an increased risk for cancers with loss/inactivation of the WT
allele inmalignant cells, defects in early FA genes have only been
weakly associated with cancer (33,52). We therefore investigated
the frequencies of aluY-mediated deletion and duplication in
UBE2T in germline DNA from 814 German patients from the Düs-
seldorf Breast Cancer Center using the PCR-based genomic detec-
tion strategy described above. Surprisingly, we did not ﬁnd any
patient with either deletion or duplication of exons 2–6 in
UBE2T, thus demonstrating that the frequency of aluY-mediated
genomic rearrangements in theUBE2T locuswas not increased in
this cancer patient population (Fig. 5B).
To ultimately deﬁne the role of UBE2T germline mutations in
patients with breast/ovarian cancer, we performed whole exome
sequencing using the IluminaHiSeq platformon 450 BRCA1/2WT
high-risk breast cancer patients. In a female patient <50 years of
age, a novel frameshift mutation in UBE2T, c.415_418insAGCC,
was detected and subsequently conﬁrmed by amplicon rese-
quencing on the MiSeq platform (>100 000× coverage). This 4-bp
insertion appeared to be the consequence of a tetranucleotide re-
peat expansion (TAATAAGCCAGCCAGCCTTCC) and led to a
frameshift at position c.416 in the open reading frame (UBE2T
415fs). The mutant reading frame encoded a protein of 158
amino acids total that included the ﬁrst 136WT amino acids nor-
mally present in UBE2T followed by 22 additional mutant amino
acids (Supplementary Material, Fig. S7). In order to undisputedly
demonstrate that this mutant UBE2T 415fs protein is not func-
tional, we expressed the mutant open reading frame in Ube2t
−/− DT40 cells. Western blotting conﬁrmed the expression of
the mutant UBE2T 415fs protein in the DT40 chicken cells
(Fig. 5C). Challenging the stably transduced Ube2t−/− cells with
increasing doses of MMC revealed that expression of the mutant
UBE2T 415fs protein did not rescue the survival of transduced
cells, in clear contrast to the Ube2T−/− DT40 cells that expressed
either the UBE2T WT or 468fs protein (Fig. 5D).
Discussion
The results of this study demonstrate that biallelic loss of func-
tion mutations in the UBE2T gene result in a new subtype of FA
with features typical for ‘early’ FA genes. This is consistent
with the UBE2T protein functioning as the main E2 conjugase
(PBMother) and the father (PB Father) and subjected to PCR. The locations of the primers are shownon the diagrams, and the primer combinations are indicated on the gel.
The sizes for the ampliﬁed PCR products of UBE2T are indicated. All bands were excised and sequenced. (C) Detection of the deletion and duplication of exons 2–6 in
genomic DNA of family members. Two distinct PCRs were developed using primers for co-ampliﬁcation of the normal as well as a mutant allele in a single reaction.
The locations of the primers and the expected sizes of the PCR products are shown in the top diagram. Genomic DNA from the patient’s (P), the Father’s (F) and the
Mother’s (M) peripheral blood (P) and EBV-transformed LCLs (LCL) was analyzed. In addition DNA from the patient’s ﬁbroblasts (ﬁbro) was used. The sizes and
identities of the PCR products are shown on the left and right sides of the gel. Mutant bands were excised and sequenced.
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Figure 3. Functional analysis of the mutations and NMD. (A) Expression of the mutant UBE2T 468fs protein in Ube2t−/− DT40 cells. Cell lysates from a normal B-cell line
(LCL), immortalized patient and normal control ﬁbroblasts, non-transduced DT40 cells (no virus), and DT40 cells transduced with the control, UBE2T 468fs or WT UBE2T
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for the FA pathway. The fact that loss-of-function germline mu-
tations in both the ubiquitin E2 conjugase, UBE2T, and the E3 lig-
ase, FANCL, result in a similar clinical and cellular phenotype is
interesting, as UBE2T is not a member of the FA core complex,
but is recruited independently to chromatin (28,29). On the
other hand, UBE2T directly interacts with FANCL and seems to
be the E2 conjugase in the cells that is absolutely necessary for
the post-translational activation of FANCD2 and FANCI bymono-
ubiquitination. Thus, the identiﬁcation of UBE2T as the 18th FA
gene is consistent with current models of the FA pathway and
conﬁrms again the intimate connection between the ‘early’ pro-
teins in the FA pathway, including FANCA/B/C/E/F/G/L/M and
UBE2T (T), which together mediate the central step activation
step, monoubiquitination of FANCD2 and FANCI.
Despite the presence of FA-typical congenital abnormalities
at birth in the patient, hematopoietic mosaicism resulted in nor-
mal peripheral blood values and normal bonemarrow cellularity
for the ﬁrst 16 years of his life. Usually, somatic alterations in
non-transformed cells remain beyond the detection limit, as
the cells do not gain a distinct phenotype. However, in FA pa-
tients, there is a strong in vivo selective growth advantage for
phenotypically normal, albeit genetically heterozygous, hemato-
poietic cells carrying a gain-of-function alteration resulting in a
WT allele. Therefore, this rare reversion in a hematopoietic
stem cell is dramatically ampliﬁed by cell differentiation and ex-
pansion over time and, therefore, can readily be studied in the
progeny of the reverted stem cells in patients with mosaicism
(17–19). As such, it is impossible to evaluate in this individual
whether patients with biallelic UBE2T mutation will develop
bone marrow failure. For this, the identiﬁcation of FA-T patients
without mosaicism might be informative.
The fact that the patient never experienced low platelet or
leukocyte counts and, considering his thalassemia minor, had
stable hemoglobin values already after the perinatal period
(Supplementary Material, Fig. S1) strongly suggests that the aluY-
mediated reversion of the maternally inherited exons 2–6 duplica-
tion in stem cells had already occurred early in life. As a reverted
hematopoietic stem cell needs ample time to repopulate both
the stem cell pool and the hematopoietic system, it appears likely
that this monoallelic recombination event in the maternal allele
occurred in utero. At the time of birth, the diagnosis of FA was
based on the typical congenital abnormalities and two positive
chromosomal breakage tests after exposure of PHA-stimulated
peripheral blood T cells to DEB. Notably, however, the two
chromosomal breakage tests performed during the ﬁrst 2 weeks
of life had already revealed that 15–20% of metaphases already
did not have breaks despite the exposure to DEB. We therefore
consider it possible that a low percentage of normal T cells with-
out hypersensitivity toDEBwas the ﬁrst sign of ongoing reversion
in the hematopoietic system. Difﬁculties in detecting the mater-
nal allele with duplication of exons 2–6 in the patient’s cDNA and
genomic DNA fromperipheral blood taken at 14 years of age (data
not shown) also supports (nearly) complete repopulation.
The molecular diagnosis of FAwas delayed in our patient due
to the unique composition of a deletion and duplication along
identical aluY elements within the locus of UBE2T. Remarkably,
not a single base was clearly mutated in our patient compared
with the UBE2T genomic sequence from the GRCh38.p2 genome
assembly by Sanger or whole exome sequencing on either the
maternal or the paternal UBE2T allele. Instead, only an abnormal
distribution of exons and introns was present between the two
alleles. In our case, even knowing the UBE2T gene defects, we
could not ﬁnd any reads in our whole exome sequencing data
that spanned either the deletion or duplication and passed the
quality ﬁlters, owing to the long polyT stretches within the
aluY repeats that cannot be passed by current sequencing tech-
niques. Therefore, although next-generation sequencing ap-
proaches are increasingly introduced into standard clinical care
(53,54), it remains to be determined what the real detection rate
of biallelic mutations in FA and other bone marrow failure pa-
tients will be in the CLIA-approved laboratory setting. Neverthe-
less, other techniques such as retroviral complementation or
protein analysis of known FA genes are well established and
can reliably be used to identify the unknown genetic defect, at
least in a research setting (37,55–58).
Alu-mediated deletions have been identiﬁed in other genetic
disorders (59,60) and also in other DNA repair/FA genes such as
BRCA2 and FANCA (61–64). These homology-mediated rearrange-
ments/deletions are increasingly recognized as an important
mechanism for introducing variations and causing mutations
in the human genome (59,65). Mechanistically, these rearrange-
ments are thought to be predominantly caused by non-homolo-
gous end joining repair, as HR usually requires a few hundred
base pairs of homology and is restricted to the S phase of the
cell cycle (66). While it is obvious that the reversion back to a nor-
mal allele in our patient’s hematopoietic systemwas the result of
an intragenic monoallelic recombination event that probably
used two identical aluY elements as the matrix, it remains un-
clear which DNA repair pathways were ultimately used for the
three different rearrangements within the UBE2T gene locus in
this family. In order to systematically investigate possible events
that could inﬂuence/trigger the genomic rearrangement between
aluY repeats, we are currently generating multicolor ﬂuorescent
reporter constructs that reﬂect the structure of the maternal
UBE2T allele with three identical aluY repeats in the same orien-
tation. After stable integration of one copy into the genome of
cells, we will inﬂict DNA double-strand breaks in these cells
using I-SceI sites and then analyze how UBE2T disruption inﬂu-
ences the types and frequency of recombination events in
these cells. We hypothesized that such genomic rearrangements
are rather uncommon; however, the detection of these rare
events was made possible in the patient’s hematopoietic system
by the strong in vivo survival advantage of the spontaneously cor-
rected stem cell(s) and their progeny during the ﬁrst 16 years of
the patient’s life.
Within thiswork, we could not elucidatewhether the deletion
and duplication of exons 2–6 deletion inUBE2T are foundermuta-
tions in humans due to their very low incidence: only two dele-
tions in almost 1700 individuals. Strikingly, the duplication of
exons 2–6 in UBE2T was not found outside of patient’s family.
vectorswere probedwithUBE2Tantibody. An antibody speciﬁc for actinwas used to visually conﬁrm equal loading. (B) Retroviral complementation ofUbe2t−/−DT40 cells
with the mutant UBE2T 468fs protein. Stable expression of the UBE2T WT (black, non-ﬁlled diamond) and 468fs (grey, triangle) proteins in Ube2t−/− DT40 cells improved
survival of the DT40 cells cultured for 3 days in increasing concentrations of MMC, compared with non-transduced (black, ﬁlled diamond) and control vector (dark grey,
dot)-transduced cells. (C) mRNA generated from thematernal allelewith the duplication is subject to NMD. cDNAwas obtained from immortalized FA 100166/1 ﬁbroblasts
that were incubated for 6 h in cycloheximide (CHX) as indicated. In addition, cDNAwas obtained from patient’s ﬁbroblasts not culturedwith DMSO (Lane 1) and fromnon-
treatedmaternal or paternal EBV-transformed B-cells (LCL). PCRwas performedwith primers speciﬁc for thematernal duplication generating a PCRproduct of 566 bp. As a
control, GAPDH cDNAwas ampliﬁed from the cDNAs with speciﬁc primers under the same conditions.
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However, difﬁculties in obtaining permission from the relatives
of the patient’s mother did not allow us to trace the origin of
the duplication further.
Finally, the detection of a germline mutation in 1 of 450 high-
risk breast cancer patients with normal BRCA1/2 suggests that
UBE2T also could be avery rare cancer susceptibility gene. The as-
sociation of ‘early’ FA genes with FANCD2 monoubiquitination
defects with increased cancer susceptibility is much weaker
(67–69) compared with the ‘late’ FA genes such as BRCA1,
BRCA2, BRIP1, PALB2 and RAD51C (4,33–35). In addition, although
aluY-mediated rearrangements in genes have been implicated in
human disorders and also cancers (59–64), we did not ﬁnd any re-
arrangement in the UBE2T locus in more than 800 breast/ovarian
cancer patients from the Düsseldorf breast cancer clinic. There-
fore, the question of whether loss-of-function mutations in
UBE2T as a bona ﬁde FA gene are associated with cancer suscep-
tibility can only be answered in future studies involving a multi-
institutional approach with large numbers of patients.
Figure 4. The cellular phenotype of human UBE2T−/− ﬁbroblasts is comparable to that of FA cells with defects in FA core complex members. (A) Survival of UBE2T−/−
ﬁbroblasts after exposure to genotoxins. An isogenic pair of UBE2T−/− ﬁbroblasts transduced with a retroviral vector encoding UBE2T or the corresponding control
vector were exposed to increasing doses of the genotoxins cisplatin, ionizing radiation and camptothecin. (B) Western blot analysis to visualize intact FANCD2 and
FANCI monoubiquitination in immortalized UBE2T−/− ﬁbroblasts after exposure to MMC by UBE2T expression. (C) Restoration of FANCD2 recruitment to sites of DNA
crosslinks by UBE2T expression. Psoralen interstrand crosslinks were induced along the track of a UVA laser in corrected and non-corrected UBE2T−/− ﬁbroblasts and
then visualized by γ-H2AX staining. FANCD2 accumulation at the sites of psoralen laser tracks only occurred in FA100166/1 cells that had been transduced with the
UBE2T expressing retroviral vector.
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Materials and Methods
Human subjects and cells
The patient and his family are descendants of Italian immigrants
to the USAwho came from Sicily. The clinical care of the patient
for the previous 16 years occurred at the Children’s Hospital of
Michigan in Detroit and at the Cincinnati Children’s Hospital in
Cincinnati. The chromosomal breakage test for the laboratory
diagnosis of FAwas performed byArleenAuerbach, International
FA Registry (5), Rockefeller University, New York. Skin ﬁbroblasts
Figure 5. UBE2Tmutations in normal individuals from Germany and Italy and in BRCA1/2WT breast cancer patients. (A) Detection of the UBE2T exons 2–6 deletion in two
healthy individuals. PCR analysis with primers for coampliﬁcation of the normal and mutant alleles with the exons 2–6 deletion were used to identify the deletion in
genomic DNA of two normal controls, N 206 from Germany and NI 264 from Northern Italy. (B) Frequencies of the UBE2T exons 2–6 deletion and duplication in normal
individuals and German breast cancer patients. The PCRs with primers for co-ampliﬁcation of the normal and two mutant alleles with the exons 2–6 deletion and
duplication were performed on genomic DNA from 850 normal control individuals from Germany and Italy. PCR analysis was also performed on genomic DNA of 814
breast cancer patients from the University of Düsseldorf breast cancer clinic. (C) The mutant UBE2T 415fs protein is stably expressed in Ube2t−/− DT40 cells. Cell
lysates from the FA 100166/1 patient ﬁbroblasts and normal control ﬁbroblasts, non-transduced Ube2t−/− DT40 cells (no vector) and Ube2t−/− DT40 cells transduced
with the control vector (vector), the WT UBE2T (UBE2T WT), the frameshift mutant UBE2T 468fs, or the frameshift mutant UBE2T 415fs vectors were immunoblotted
and probed with the polyclonal UBE2T antibody. (D) Expression of the mutant UBE2T 415fs protein does not correct the MMC hypersensitivity of Ube2t−/− DT40 cells.
Expression of the human UBE2T WT (blue line) and 468fs protein (green) increased the survival rates of Ube2t−/− DT40 chicken cells during culture with increasing
concentrations of MMC for 3 days. The UBE2T 415fs mutant protein (red) did not confer any survival advantage relative to that of non-transduced (no virus, black line)
and control vector-transduced (vector, blue) cells.
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from the patient were sampled for genetic analysis at the age of
2 years andwere kindly provided by Dr Richard Harris, Cincinnati
Children’s Hospital, Cincinnati, OH. FANCL-deﬁcient primary ﬁ-
broblasts were a kind gift of Dr Auerbach, Rockefeller University,
NY (70). Primary FANCG- and FANCQ/ERCC4-deﬁcient reference
ﬁbroblast cells were kindly provided by Dr Detlev Schindler,
Department of Human Genetics, University of Würzburg,
Germany (2,38). Peripheral blood or DNA of healthy individuals
was obtained with their informed consent. All studies were ap-
proved by the local institutional review boards/ethics commit-
tees. The DNA from the high-risk breast cancer patients was
deidentiﬁed clinical samples from a subset of U.S. states allowing
such anonymization and devoid of unique BRCA sequence var-
iants that might have made it possible to re-identify the patients
on the basis of their genotypes.
Fanconi anemia cellswere grown in 5%O2 as described (13,50).
Adherent cells were grown in high glucose DMEM, and non-ad-
herent cells were cultured in RPMI1640. Both media were supple-
mented with 10% fetal bovine serum (FBS), 1% glutamine and 1%
penicillin/streptomycin (all fromGibco BRL/Invitrogen). DT40 cell
medium was additionally supplemented as described (28,29).
For chromosomal breakage testing, primary ﬁbroblasts from a
healthy donor (NL1433889), the FANCG−/− reference patient, and
the UBE2T−/− patient FA 100166/1 were cultured in high glucose
DMEM containing 20% FBS, 1% penicillin/streptomycin and 1 m
sodium pyruvate (all from Gibco BRL). Cells were cultured in 0,
0.01 or 0.1 µg/ml DEB for 48 h, then washed, and replenished
with fresh medium. Subsequently, cells were exposed to
200 µg/ml colcemid for 7–8 h, harvested, andﬁxedusing standard
protocols (22,36). Metaphase spreads were prepared, GtG-banded
and analyzed under a brightﬁeld microscope.
Plasmids and retroviruses
The retroviral and lentiviral vector backbones used in this study
were described previously (13,50,71,72). The human UBE2T cDNA
was a kind gift of Dr Anindya Dutta, University of Virginia School
of Medicine, Charlottesville, VA (27). The open reading framewas
ampliﬁed with primers 5′ NotI and 3′ BamH I to add the necessary
restriction sites for cloning into the pS91-IRES-NEO vector.
cDNAs for human FANCL, FAAP20, FAAP24, FAAP100, UBE2T and
UBE2W were purchased from Geneart (Invitrogen). The SV40
large T cDNA was a kind gift of Dr Valerie Schumacher, Human
Genetics, Düsseldorf, Germany. All vectors were controlled by ca-
pillary Sanger sequencing prior to generating replication incom-
petent retroviral supernatants. Retroviral vectors were stable
packaged in PG13 cells as previously described (13,50). Lentiviral
vectors were produced with the GalvTM envelope as previously
described (72,73). All adherent cells were transduced in the pres-
ence of 7.5 µg/ml polybrene (Sigma-Aldrich), and all non-adher-
ent cells were exposed to virus on the recombinant ﬁbronectin
fragment CH-296 (Takara Shuzo) as described previously (74).
Flow cytometry for cell cycle analysis and survival
Cell cycle analysis was performed as described (13,50). Brieﬂy,
G418 (Geneticin, Gibco BRL)- or puromycin (Sigma-Aldrich)-re-
sistant primary ﬁbroblasts were incubated for 3 days with in-
creasing concentrations of MMC and then harvested, ﬁxed,
stained with propidum iodine and analyzed for their cell cycle
distribution on a FACSCalibur (BD Biosciences). DT40 cells were
grown for 3 days in increasing concentrations of MMC and ana-
lyzed on the FACSCalibur using propidium iodine staining to dis-
criminate between live and dead cells. Flow cytometric datawere
analyzed using the Cell Quest (BD Biosciences) or Modﬁt (Verity
Software House, Topsham, ME, USA) software programs. Data
are shown as mean ± standard error of the mean (SEM) or are
from a representative experiment.
Western blotting
For FANCD2 western blotting, cell pellets were lysed and protein
lysate was measured using the Pierce BCA Protein Assay Kit
(Thermo Scientiﬁc, 23227). Brieﬂy, 20 µg protein lysates were
loaded onto a 7% tris acetate gel and run at 120 V for 7 h. The
blot was transferred overnight onto nitrocellulose at 4°C in 20%
methanol, Tris glycine buffer (1X) at 20 V. The blot was blocked
in phosphate-buffered saline (PBS) with 0.01% Tween 20 (PBST)
containing 5% skim milk for 30 min followed by FANCD2 anti-
body (Thermo Scientiﬁc, MA1-16570) diluted at 1:5000 for 3 h.
Subsequently, the blot waswashed three times in PBST and incu-
bated with anti-mouse IgG horseradish peroxidase (HRP)-conju-
gated secondary antibody (Promega, W402B; 1:5000). Finally, the
blot waswashed three times, treatedwith the Pierce ECLWestern
Substrate, and exposed using a Bio-Rad imager. Analysiswas per-
formed with Bio-Rad Image Lab software 2.0. The blot was
stripped using GM Biosciences One-Minute Western Blot Strip-
ping Buffer (GM 6001), and the western protocol was repeated
using RAD50 (GeneTex, GTX70228; 1:5000) as the primary
antibody.
For the UBE2Twestern blotting, 20 µg protein lysateswere run
on a 4–12% Bis–Tris gel at 120 V for 1.5 h. The Western protocol
was the same as above using the non-commercial UBE2T anti-
body that we have previously reported (44) (1:1000) and anti-
sheep as the secondary antibody (Promega). The blot was
stripped and incubated with antibody to glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH; GeneTex, GTX627408; 1:5000) or
β-actin (Sigma-Aldrich, A5441; 1:5000).
To detect FANCI, 40 µg protein lysate was separated on an 8%
Tris–glycine gel at 80 V for 0.5 h plus 180 V for 2 h. The blot was
transferred 2 h onto nitrocellulose in 20% methanol, Tris glycine
buffer (1X) at 30 V. The blot was blocked in Tris-buffered saline
(TBS) with 0.1% Tween 20 (TBST) containing 5% skim milk for
30 min followed by FANCI antibody (Bethyl, A300-212A) diluted
at 1:2000 for 3 h. Subsequently, the blot was washed three
times in TBST and incubated with anti-rabbit IgG horseradish
peroxidase (HRP)-conjugated secondary antibody (Promega).
Whole exome sequencing (WES)
WES on the primary FA 100166/1 cells was performed at the Cen-
ter for Inherited Disease Research (CIDR, Johns Hopkins Univer-
sity) as described previously (75). Brieﬂy, exonic sequences
were captured using the Agilent SureSelect 51 Mb Human All
Exon Kit, and paired-end sequencing was performed on the Illu-
mina HiSeq 2000 system, using Flowcell version 3 and TruSeq
Cluster Kit version 3. Primary analysiswas done usingHiSeq Con-
trols Software and RuntimeAnalysis Software. The CIDRSeqSuite
version 3.0.1 pipelinewas used for secondary bioinformatics ana-
lysis, which consistsmainly of alignment using BurrowsWheeler
Aligner version 0.5.9 to the human genome reference sequence
(build hg19) and applying the Genome Analysis Toolkit (GATK)
version 1.4-29-gcd352f5 to perform local realignment and base
quality score recalibration. Duplicate molecules were ﬂagged
and mate-pair information synchronized using Picard version
1.57, and the GATK Uniﬁed Genotyper was used for variant call-
ing. ANNOVAR was used to annotate variants for location and
predicted effect on the protein, corresponding gene information,
Human Molecular Genetics, 2015, Vol. 24, No. 18 | 5103
 at U
niversity of D
undee on July 1, 2016
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
allele frequencies across multiple databases, and predicted vari-
ant effects.
WES using the MySeq platform was performed on genomic
DNAextracted byQIAsymphony using theDSPDNAMidi kit (Qia-
gen) from peripheral blood of 450 BRCA1/2 wild-type breast can-
cer patientswith an age at diagnosis <50 years, anonymized from
the US clinical testing sample ﬂow of Myriad Genetic Laborator-
ies, using the Nextra Enrichment Kit (DC-121-1208, Illumina).
JAligner was used for the initial mapping, followed by the variant
calling, call quality assessment and review using in-house-
developed software. The novel frameshift mutation in UBE2T,
c.415_418insAGCC, was subsequently conﬁrmed by amplicon re-
sequencing on the MySeq platform (with the amplicon spanning
chromosome 1 hg19/GRCh37 locations 202 302 051–202 302 350
using primer sequences GTTTCTGTCTTGCATGCTTCTC and
CCTCTGCAACACATATCCTACC). To avoid alignment efﬁciency
biases caused by the presence of the insertion, the allele ratios
were subsequently requantiﬁed using local realignment with
the reference and mutated sequences.
Sanger sequencing and PCR of cDNA
Screening for mutations in UBE2T was carried out using direct
genomic sequencing. The PCR primers designed to amplify and
sequence all exons and adjacent introns of the UBE2T gene (Re-
fSeq: NM_014176.3) are listed in Table 1. Sequencing was per-
formed using an ABI 3730xl DNA analyzer (Applied Biosystems).
To detect the deletion of exons 2–6 in UBE2T, RNA isolated from
peripheral blood, T cells expanded on CD3/CD28 immobilized
antibodies (55), or ﬁbroblasts using the RNeasy Mini Kit (Qiagen)
was retrotranscribed with RNase H+ MMLV reverse transcriptase
(iScript™ cDNA Synthesis Kit, Bio-Rad) and PCR-ampliﬁed with
exon primers 1F and 7R. To detect the duplication of exons 2–6
in UBE2T, forward primer 6F (exon 6) in combination with any re-
verse primer located in exons 1–7 aswell as with forward (2F) and
reverse (2R) primers located in exon 2 were used (EmeraldAmp
MAX PCR Master Mix [Takara] and/or Platinum®Taq DNA
Polymerase [Invitrogen]). All abnormally sized PCR fragments
corresponding to the mutant allele(s) were gel-extracted (Gel ex-
traction kit, Qiagen) and cloned into pGEM-T vector (pGEM®-T
Easy Vector System, Promega). Positive colonies were puriﬁed
using the Wizard® Plus Minipreps DNA Puriﬁcation System (Pro-
mega) and capillary sequenced. Long-range PCR was performed
to detect and further characterize duplicated and deleted alleles
using genomic DNA. The same PCR conditions were used.
PCR for detection of the duplication and deletion
of exons 2–6 in genomic DNA
Genomic DNA isolated from whole blood, ﬁbroblasts or a newly
established EBV-transformed B-cell line using QiaAmp DNA
Mini Kit (Qiagen) were PCR-ampliﬁed with forward primer 1_7F,
reverse primer 1_7R and additional reverse primer ivs1R
(Fig. 2C, Table 2) using EmeraldAmp MAX PCR Master Mix and/or
Platinum®Taq DNA polymerase. A band of 1750 bpwas ampliﬁed
from the deleted allelewith the primers 1_7F and 1_7R, whereas a
second reverse primer ivs1R allowed ampliﬁcation of the control
band of 1066 bp (Fig. 2C). For detection of the duplication, add-
itional forward intron 5 (ivs5F) and reverse intron 1 (ivs1R)
primers (Fig. 2C, Table 2) were designed in close proximity of
repetitive elements. These two primers when combined
with exon 7 (7R) primers allowed us to co-amplify a control
band of 1360 bp and a duplication-speciﬁc band of 769 bp in the
same reaction (Fig. 2C). All PCR fragments corresponding to the
mutant alleles were gel-extracted (Gel extraction kit, Qiagen)
and cloned into pGEM-T vector (pGEM®-T Easy Vector System,
Promega). Positive colonies were puriﬁed using the Wizard®
Plus Minipreps DNA Puriﬁcation System (Promega) and capillary
sequenced.
For detecting the deletion and duplication of exons 2–6 in
UBE2T in the genomic DNA of healthy donors from Germany
and Italy and from German breast cancer patients, DNA was ex-
tracted from the blood samples using the DNeasy 96 Blood & Tis-
sue Kit (Qiagen). For the ﬁbroblasts and lymphoblastoid cell lines
(LCLs), DNA was extracted using QIAShredder and QIAamp DNA
Mini Kit (both Qiagen) and ampliﬁed by PCR with 30 cycles. PCR
was performed on 50 ng template with 250 pmol of each primer
for 30 cycles using the primers listed in Table 2. The deletion
analysis was ampliﬁed bymy-Budget Taq-DNA-polymerase (Bio-
budget) supplemented by 12.5 mMgCl2 per reaction. The dupli-
cation reaction contained HotStarTaq DNA polymerase (Qiagen)
and 2.5 m MgCl2. The PCR products from the blood samples,
normal LCLs as a negative control, the patient’s ﬁbroblasts as a
positive control, and a water control were separated on 0.8%
agarose gels, stained with ethidium bromide and visualized.
Celltiter 96 AQueous non-radioactive cell proliferation
assay (MTS assay)
Immortalized 3000 cells of 100166/1T cells transduced with the
retroviral control or UBE2T vectors were seeded in wells of a 96-
well plate. Five wells were plated for each dose of genotoxin.
Cells were allowed to adhere for a minimum of 8 h before add-
ition of the indicated doses of genotoxin. Cells were left to grow
for 4 days at 37°C in a humidiﬁed, 5% CO2 atmosphere before
Table 2. Primers
cDNA primers for cloning of UBE2T into S91-IRES-NEO
5′ NotI CATGCGGCCGCATGCAGAGAGCTTCA
3′ BamH I GTAGGATCCCTAAACATCAGGATG
cDNA primers
1F AGTCAGAGGTCGCGCAGGCGCTG
1R CCCTCACAACGCAGCAA
2F TGCATCCCAGGCAGCTCTTA
2R TAGAAGGAACCACACACAGTTC
3R CATAAGGTGTGTTGGCTCCACCTA
4R CATCCAGACAAATCCTTCCAGCAG
5R TGGGTTCTGACATGAGCAGCTGAA
6F CAAGAATGCCAGACAGTGGACAGA
6R CTTGAGGAAGGCTGGCTTATTA
7R GGTAGGCAACTTAGATCACCTTGGCA
Genomic primers for the duplicationa
ivs5F CCTCTGCAACACATATCCTACC
ivs1R CCTCTGTGCGTCTACATCTATTT
e7R TCTATGCCTACTAGCTGACTGG
Genomic primers for the deletiona
1_7F GCTTCTTTCCCGGTGGATTA
1_7R CCCAGACACACATTCAGGATAAA
ivs1R AAACTCATGCTTCAGCCACACTGC
Primers for NMD detectiona
Exon 1 tgtaaaacgacggccagtAGTCAGAGGTCG
CGCAGGCGCTGb
duplication-speciﬁc gcctgggatgcActtttgtttctgc
aAll primers shown as 5′ to 3′, F = forward, R = reverse.
bContains the M13 forward binding site (small letters).
cUnderlined A indicates the site of the junction in cDNA.
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MTS assays were performed according to the manufacturer’s in-
structions (Promega). Brieﬂy, 20 μl of combined MTS/PMS solu-
tion was added to cells in each well, and cells were incubated
for 1.5 h at 37°C in a humidiﬁed, 5% CO2 atmosphere before the
absorbance at 490 nm was measured using an enzyme-linked
immunosorbent assay plate reader. Data are presented as the
mean of three independent experiments.
Psoralen-induced ICL recruitment assays
Cells were plated on glass-bottomed dishes (WPI) and pre-treated
with 50 μM psoralen (Sigma) 1 h before psoralen was activated
using a 360-n laser scanning 5X at 25% energy across cell nuclei
(PALMmicroscope, Carl Zeiss). Cells were ﬁxed 30 min post-laser
irradiation with 2% paraformaldehyde for 10 min at room tem-
perature. Cells were then permeabilized with 0.2% Triton X-100
in PBS for 10 min at room temperature before several washes in
PBS and incubation in blocking solution (PBS containing 3%
IgG-free bovine serum albumin (Jackson Immunoresearch) and
0.2% Tween 20) for 1 h. Cells were then incubated with the indi-
cated primary antibodies (1 μg/ml) in blocking solution for 1 h.
After extensive washing in PBS containing 0.2% Tween 20, cells
were incubated with secondary antibodies (2 μg/ml) conjugated
to ﬂuorescein isothiocyanate (FITC; for γ-H2AX) or Texas Red
(for FANCD2) for 45 min. Cells were washed thoroughly and
stained with DAPI-Hydromount for 5 min before being covered
with a glass coverslip. Cell staining was viewed using a Deltavi-
sion DV3 wideﬁeld deconvolution microscope mounted on a
Nikon Diaphot inverted microscope, and images were decon-
volved after acquisition. The γ-H2AX antibody was purchased
from Millipore (#05-636), the FANCD2 monoclonal antibody
from Abcam (#ab2187), and the secondary Alexa Fluor-conju-
gated antibodies were obtained from Invitrogen.
NMD in FA patient 100166/1 ﬁbroblasts
Oneday prior to cycloheximide treatment,ﬁbroblastswere plated
in 6-well tissue-culture dishes such that the cells were 80–90%
conﬂuent the following day. The cells were treated with 25, 50
or 100 μg/ml cycloheximide dissolved in dimethyl sulfoxide
(DMSO; Sigma-Aldrich). As additional controls, cells were treated
with DMSO alone or just grown in medium without DMSO. After
6 h, the cells werewashed twicewith PBS and lysed directly in the
well for isolation of total mRNA using the Qiagen RNeasy kit.
cDNA was synthesized using random hexamers and the iScript
cDNA Synthesis Kit according to the manufacturer’s recommen-
dations (Bio-Rad). PCR was performed with the EmeraldAmp
MAX PCRMaster Mix and gene-speciﬁc primers. The forward pri-
mer was located within exon 1 (Table 2) and contained the M13
forward binding site. The reverse primer was speciﬁc for the
UBE2T duplication (Table 2) as it encompassed a unique region
of the mutated cDNA that is part of the normally non-translated
5′ region of exon 2 and the 3′ region of exon 6 at the junction site.
The PCR product was 565 bp.
Supplementary Material
Supplementary Material is available at HMG online.
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